Table 3. Treatment-related non-haematological adverse eventsa during and after cycle one occurring in ⩾5% of patients for all cohorts combined (N=33).

	Cycle 1, n (%)		After cycle 1, n (%)
Adverse event	All grades	Grade 3	All grades	Grade 3
Fatigue	11 (33)	0	10 (30)	1 (3)
Nausea	10 (30)	0	5 (15)	1 (3)
Diarrhoea	6 (18)	0	10 (30)	0
Constipation	4 (12)	0	3 (9)	0
Rash	4 (12)	0	2 (6)	0
Vomiting	2 (6)	0	2 (6)	1 (3)
Peripheral oedema	3 (9)	0	2 (6)	0
Dyspnea	3 (9)	0	1 (3)	0
Anorexia	1 (3)	0	3 (9)	0
Pyrexia	1 (3)	0	2 (6)	0
Epistaxis	0	0	4 (12)	0
Flatulence	0	0	3 (9)	0
Mucosal inflammation	0	0	3 (9)	0
Chills	0	0	2 (6)	0
Muscular weakness	0	0	2 (6)	0
Cough	0	0	2 (6)	0
Alopecia	0	0	2 (6)	0

^aAdverse events were defined as treatment-related based on having a relationship to study drug reported as ‘yes’ or ‘unknown’. No treatment-related, grade 4/5 adverse events were reported.